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Background: Active targeting by specific antibodies combined with nanoparticles is a promising 
technology for cancer imaging and detection by magnetic resonance imaging (MRI). The aim 
of the present study is to investigate whether the systemic delivery of antivascular endothelial 
growth factor antibodies conjugating to the surface of functionalized supermagnetic iron oxide 
nanoparticles (anti-VEGF-NPs) led to target-specific accumulation in the tumor.
Methods: The VEGF expression in human colon cancer and in Balb/c mice bearing colon 
cancers was examined by immunohistochemistry. The distribution of these anti-VEGF-NPs 
particles or NPs particles were evaluated by MRI at days 1, 2, or 9 after the injection into the 
jugular vein of Balb/c mice bearing colon cancers. Tumor and normal tissues (liver, spleen, 
lung, and kidney) were collected and were examined by Prussian blue staining to determine the 
presence and distribution of NPs in the tissue sections.
Results: VEGF is highly expressed in human and mouse colon cancer tissues. MRI showed 
significant changes in the T*2 signal and T2 relaxation in the anti-VEGF-NP- injected-mice, but 
not in mice injected with NP alone. Examination of paraffin sections of tumor tissues stained 
for the iron constituent of the NPs with Prussian blue revealed a strong blue reaction in the 
tumors of anti-VEGF-NP-treated mice, but only a weak reaction in mice injected with NPs. 
In both groups, at all time points, Prussian blue-stained liver and spleen sections showed only 
light staining, while stained cells were rarely detected in kidney and lung sections.   Transmission 
electron microscopy showed that many more electron-dense particles were present in endothelial 
cells, tumor cells, and extracellular matrix in tumor tissues in mice injected with anti-VEGF-
NPs than in NP-injected mice.
Conclusion: These results demonstrated in vivo tumor targeting and efficient accumula-
tion of anti-VEGF-NPs in tumor tissues after systemic delivery in a colon cancer model, 
showing that anti-VEGF-NPs have potential for use as a molecular-targeted tumor imaging 
agent in vivo.
Keywords: nanoparticles, vascular endothelial growth factor, colon tumor, magnetic resonance 
imaging, transmission electron microscopy
Introduction
Cancer remains the leading cause of death in the world and colorectal cancer 
accounts for nearly half of the annual cancer deaths, with nearly 1.2 million 
new cases of colon cancers being diagnosed each year.1 Despite advances in 
the understanding of the pathogenesis, the discovery of cancer biomarkers, and 
improvements in surgery, radiotherapy, and chemotherapy, the overall survival 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2833
ORIgINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S32154International Journal of Nanomedicine 2012:7
rate from cancer has not significantly improved in 
the past two decades.2 Novel tools or agents for early 
detection and diagnosis of cancers are therefore urgently 
required to increase patient survival. Magnetic resonance 
imaging (MRI) provides superb image resolution and 
is often used as a tool for cancer detection. Gadolinium 
diethylenetriaminopentaacetic acid is often used as the 
magnetic contrast agent to obtain contrast enhancement and 
signal amplification during MRI, but has a very short blood 
retention time, low bioavailability, and high toxicity.3 
Recently, supermagnetic iron oxide nanoparticles (NPs) 
lacking these three drawbacks became available as novel 
diagnostic tools for noninvasively assessing the benefit 
of therapies, identifying early molecular changes and 
reoccurrence associated with cancer, and are being used 
in new targeted and specific therapies.4
Tumor growth and metastatic dissemination largely 
depend on new blood vessel formation (angiogenesis), and 
vascular endothelial growth factor (VEGF) is a key regula-
tor of this process.6 VEGF is an endothelial cell-specific 
mitogen used in vitro, and an angiogenic inducer in a vari-
ety of in vivo contexts,6 and is also a vascular permeability 
factor.7 In situ hybridization studies have demonstrated high 
VEGF mRNA levels in the majority of human tumors.8–11 
Moreover, VEGF protein expression is not restricted to the 
advanced stages of colonic cancer, but can also be observed 
in the premalignant stages of tumor development when 
compared to normal colonic mucosa.12 As VEGF expression 
is localized in the tumor, and VEGF is expressed during 
the pathogenesis of cancer, this provides an opportunity for 
designing VEGF-targeted approaches for cancer detection 
and treatment.13,14 Active targeting by specific antibodies 
combined with nanosize superparamagnetic iron oxide is a 
promising technology for MRI technology.15 In this study, 
we combined an anti-VEGF antibody as a tumor-targeting 
ligand and dextran-coated Fe3O4 NPs to generate anti-VEGF 
antibody-conjugated dextran-coated Fe3O4 nanoparticles 
(anti-VEGF-NPs) that selectively accumulated in the tumor 
of CT26 tumor-bearing mice in vivo with a high efficiency, 
allowing the location of the colon tumors to be delineated 
by MRI. The anti-VEGF-NPs specifically bound to, and 
were internalized by, VEGF-expressing endothelial cells and 
tumor cells, as shown by Prussian blue staining and trans-
mission electron microscopy (TEM). Our results show that 
anti-VEGF-NPs can be used as an antibody-targeted MRI 
contrast agent for the in vivo detection of VEGF-expressing 
tumors.
Materials and methods
Synthesis of dextran-coated Fe3O4 
nanoparticles (NP) and anti-VEgF 
antibody-conjugated dextran-coated 
Fe3O4 nanoparticles (anti-VEgF-NP)
The protocol for the synthesis of the magnetic Fe3O4 nano-
particles was proposed by MagQu Co, Ltd (Taipei,   Taiwan) 
and has been described previously.16 Briefly, a   ferrite solu-
tion containing a stoichiometric 1:2 ratio of   ferrous sulfate 
heptahydrate (FeSO4 ⋅ 7H2O) and ferric c  hloride hexahydrate 
(FeCl3 ⋅ 6H2O) was mixed with an equal volume of aque-
ous dextran, which acts as a surfactant for Fe3O4   particles 
dispersed in water. The mixture was heated to 70°C–90°C 
and titrated with a strong base solution to form black Fe3O4 
particles.
Aggregates and excess unbound dextran were removed by 
centrifugation and gel filtration chromatography to obtain a 
highly concentrated magnetic fluid containing dextran-coated 
Fe3O4 NPs. The desired concentration of the magnetic reagent 
was produced by diluting the highly concentrated magnetic 
fluid with phosphate-buffered saline (PBS; pH 7.4). To bind 
the anti-VEGF Abs (sc507; Santa Cruz Biotechnology, 
Santa Cruz, CA) to the dextran on the outer shell of the 
magnetic nanoparticles, NaIO4 solution was added to the 
magnetic solution to oxide dextran and create aldehyde 
groups, which then reacted with amino groups on the anti-
VEGF antibody, resulting in covalent attachment. Magnetic 
separation was then used to separate the anti-VEGF-NPs 
(MF-VEG-0060, MagQu) from nonbound anti-VEGF 
antibody. The concentration of the magnetic reagent in terms 
of magnetism was 0.3 emu/g (∼3.6 mg-Fe/mL). The sizes of 
NPs and anti-VEGF-NPs were measured with two different 
methods, dynamic light scattering (DLS) and transmission 
electron microscopy (TEM). In the DLS assay, the samples 
were diluted in double-distilled water and examined using 
a Nanotrac-150 (Microtrac Inc, Montgomeryville PA). In 
TEM observation, the particles were negatively stained with 
sodium phosphotungstate solution.
Cancer cell line
CT26 cells, a murine colon adenocarcinoma cell line (ATCC, 
Manassas, VA), were grown in Roswell Park Memorial 
Institute medium containing penicillin-streptomycin (1%) 
and fetal bovine serum (FBS, 10%; Biological Industries Ltd, 
Beit Ahemeq, Israel) at 37°C in a humidified atmosphere of 
95% air and 5% CO2.
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Establishment of the colon tumor model
Forty-eight Balb/c mice of either sex (6 to 8 weeks of age) 
were purchased from BioLASCO (Taipei, Taiwan). All 
procedures involving experimental animals were performed 
in accordance with the guidelines for animal care of the 
National Taiwan University and complied with the Guide for 
the Care and Use of Laboratory Animals. Colon tumors were 
generated in mice by subcutaneous implantation of 5 × 105 
CT26 cells suspended in 150 µL of Roswell Park Memorial 
Institute medium. After injection, the animals were given 
food and water ad libitum, and were housed under normal 
conditions with a 12-hour light/dark cycle and were used for 
experiments after 14 days.
MRI scan in vivo
On day 14 after tumor injection, images were obtained under 
isoflurane anesthesia (1% to 2% isoflurane; 1 L O2) at the 7T 
animal MRI Core Laboratory of the Neurobiology and Cog-
nitive Science Center (National Taiwan University, Taipei). 
To follow MRI contrast changes, the mice were then injected 
through the jugular vein with anti-VEGF-NPs or NPs (10 mg/
Kg of body weight) in 100 µL of PBS and imaged at differ-
ent time points (1 day, 2 days, and 9 days) according to the 
previous studies.17,18 Blood pressure and heart rate were mea-
sured before and after injection. Images were taken pre- and 
post-injection to evaluate the contrast enhancement using the 
target-specific contrast agent. For MRI images, a 7-Tesla MRI 
system (Burker BioSpin Biospec 7030, Ettlingen, Germany) 
with a 30 cm horizontal bore, a 75 Gauss/cm gradient, and a 
35 mm transmit-receive birdcage volume coil was used. Axial 
images over the flank were acquired with a 2.0 cm square 
field of view and 1.0 mm slice thickness. MRI was performed 
using a T2*-weighted gradient echo pulse sequence (repetition 
time/echo time 244/4.3 milliseconds, number of excitations 8, 
matrix = 256 × 256, resolution 78 × 78 × 1000 µm). The signal 
of the phantom was used to normalize the signals.
Preparation of cell and tissue lysates  
and Western blot analysis
Western blot analyses were performed as described previ-
ously.19 To prepare cell lysates, the cells or tissue were lysed 
for 1 hour at 4°C in lysis buffer (20 mM Tris-HCl, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM 
phenylmethylsulfonyl fluoride, pH 7.4). The lysate was then 
centrifuged at 4000 g for 30 min at 4°C, and the supernatant 
retained. Samples of cell lysate (25 µg of protein) were 
subjected to 15% sodium dodecyl sulfate polyacrylamide 
gel electrophoresis and transferred to polyvinylidene fluo-
ride membranes, which were then treated for 1 hour at room 
temperature with 3% nonfat milk in Tris-buffered saline 
(50 mM TrisHCl, pH 7.4, 150 mM NaC) containing 0.1% 
Tween 20 (TBST) to block nonspecific binding of   antibodies. 
The membranes were then incubated overnight at 4°C with 
rabbit antibodies against human VEGF (1:1000; Santa Cruz 
Biotechnology) diluted in Tris-buffered saline with Tween 
containing 0.1% bovine serum albumin, then again for 
1 hour at room temperature with horseradish peroxidase-
conjugated goat anti-rabbit immunoglobulin-G antibodies 
(1:2000 in Tris-buffered saline with Tween, 0.1% bovine 
serum albumin; Santa Cruz Biotechnology), which are 
bound antibodies being detected using Chemiluminescence 
Reagent Plus (NEN, Boston, MA). The intensity of each 
band was quantified using a densitometer. Antibodies against 
glyceraldehyde-3-phosphate dehydrogenase (1:5000; Santa 
Cruz Biotechnology) were used as loading controls.
Immunohistochemical procedures
Immunohistochemistry was used to evaluate the VEGF 
expression in both human colon tumors and a mouse model 
of colon tumor and to compare the difference of its expres-
sion between tumor tissues and normal tissues. Human tumor 
samples were processed with the approval of the National 
Taiwan University Hospital and Research Ethics Boards. 
Human and mouse tumor tissues and normal mouse organs 
(liver, kidney, lung, and spleen) were fixed in 4% paraform-
aldehyde, embedded in paraffin, and sectioned for detection 
of VEGF expression using immunohistochemical staining. 
The first of two serial sections was stained overnight at 4°C 
with rabbit anti-VEGF antibody (1:150 dilution in PBS; 
Santa Cruz Biotechnology), washed twice with PBS, and then 
incubated for 1 hour at 37°C with fluorescein isothiocyanate-
conjugated goat anti-rabbit immunoglobulin-G antibodies 
(1:200 dilution in PBS; Santa Cruz Biotechnology), and 
observed under the fluorescence microscope. The second 
serial section was stained with hematoxylin-eosin staining.
Histological analysis by Prussian  
blue staining
Mice were sacrificed at days 1, 2, or 9 after injection of 
anti-VEGF-NPs or NPs, and tumor and normal tissues 
(liver, spleen, lung, and kidney) were collected. Paraffin 
tissue sections were examined by Prussian blue staining to 
determine the presence and distribution of NPs in the tissue 
sections. The paraffin sections were incubated for 30 min at 
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room temperature with staining solution (a 1:1 mixture of 
4% potassium ferrocyanide and 4% hydrochloric acid). After 
counterstaining with 0.5% neutral red solution, the slides 
were then examined under a light microscope.
TEM
To examine the detailed distribution of anti-VEGF-NPs and 
NPs, TEM was performed on tumor samples taken 1 day after 
nanoparticle injection. Tumor samples were postfixed for 
1 hour with 1% osmium tetroxide in 0.1 M phosphate buffer, 
dehydrated in a graded series of ethanols, and embedded in 
Epon. Thin sections were picked up on 150-mesh copper grids, 
lightly stained with lead citrate, and scanned in a Hitachi H7100 
(Hitachi, Tokyo, Japan) at 100 kV , with high-resolution digital 
images being obtained using an AMT digital CCD camera.
Statistical analysis of data
All values are presented as the mean ± SEM and were 
analyzed using Student’s t-test. Statistical significance was 
determined as P , 0.05.
Results
VEgF is highly expressed in human  
and mouse colon cancer tissues
VEGF expression in human and mouse colon tissue was 
  evaluated by immunofluorescent staining. In surgically 
removed normal tissue and tumor tissue in human colon tumor 
samples, VEGF immunoreactivity was strong in the tumor 
tissue, but undetectable in the normal tissue (  Figure 1A). 
Colon tumors were easily distinguishable from the healthy 
colon when examined and visualized by hematoxylin-eosin 
staining. In tumor sections from CT26-bearing mice, strong 
VEGF immunoreactivity was detected   specifically in the 
tumors (Figure 1B). VEGF expression was weak in the spleen 
and undetectable in the lung, liver, and kidney (Figure 1B). 
To confirm the level of expression of VEGF in vitro and in 
vivo, Western blotting was used. As shown in Figure 1C, 
high VEGF expression was detected not only in cultured 
CT26 cells, but also in cancer tissue in the mouse model, 
while VEGF expression was barely detectable in the spleen 
and undetectable in the lung, liver, and kidney. These results 
Figure 1 Strong expression of VEGF in human and mouse colon tumors as shown by immunofluorescent staining and Western blotting. (A) Serial sections from N and T 
in colon tumor specimens from P1 and P2 were stained for VEgF (upper panels) or with HE staining (lower panels). The arrows indicate VEgF expression colocalized with 
tumor cells. Scale bar = 100 µm. (B) Fluorescence and light microscopic images of mouse tumor sections. Serial sections from tumor, lung, spleen, liver, and kidney of CT26-
bearing mice were stained for VEgF (upper panels) or HE (lower panel). Scale bar = 100 µm. (C) VEgF levels in CT26 cell lysates and in tissue lysates from tumor, lung, 
spleen, liver, and kidney of CT26-bearing mice measured by Western blotting. gAPDH was used as the loading control. 
Abbreviations: gAPDH, glyceraldehyde-3-phosphate dehyodrogenase; HE, hematoxylin and eosin; N, normal tissue; P, patient; T, tumor tissue; VEgF, vascular endothelial 
growth factor.
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Figure  2  In  vivo  MRI  of  anti-VEgF-NPs  or  NPs  injected  into  mice  bearing 
colon tumors. (A) Particle size and distribution of NPs and anti-VEgF-NPs were 
determined by DLS method. (B) Representative TEM image of NPs and anti-VEgF-
NPs; the particle sizes ranged between 15–30 and 45–65 nm, respectively. Scale 
bar = 50 nm. (C) In vivo MRI of mice bearing colon tumors at the indicated time 
points (1 d, 2 d, and 9 d) after intravenous injection of 10 mg Fe/Kg of NPs (left 
panels) or anti-VEgF-NPs (right panels).
Notes: The same mice before injection of anti-VEgF-NPs or NPs were used as 
controls. The dashed lines and arrows indicate the location of the colon tumor and 
the location of the nanoparticles, respectively.
Abbreviations: MRI, magnetic resonance imaging; VEgNF-NPs, vascular endothelial 
growth factor nanoparticles; NPs, nanoparticles; DLS, dynamic light scattering; TEM, 
transmission electron microscopy; d, day.
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indicate that VEGF is highly expressed in tumor cells and 
that the anti-VEGF antibody bound to its target, VEGF, in 
both mouse and human tumor tissue sections, making this 
molecule as an ideal target for positive selection of VEGF-
targeted imaging agents. In addition, this mouse model was 
suitable for in vivo assessment of tumor targeting/imaging 
using anti-VEGF antibody.
Anti-VEgF-NPs, but not NPs,  
specifically target colon cancer  
in vivo as shown by MRI
To permit evaluation of VEGF expression using light 
microscopy or MRI and to develop a VEGF-targeted imag-
ing agent, we coupled anti-VEGF antibody to dextran-coated 
Fe3O4 NPs to form anti-VEGF-NPs. Particle size and size 
distribution of NPs and anti-VEGF-NPs were determined by 
DLS (Figure 2A). The diameters of NPs and anti-VEGF-NPs 
were around 49.7 nm and 57.2 nm, respectively. In addition, 
the Fe3O4-based NPs were monodisperse, as shown in the 
representative TEM images in Figure 2B. Bioconjugation of 
anti-VEGF antibody to NPs increased the average particle 
size from 15–30 nm to 45–65 nm (Figure 2B). To evalu-
ate the tumor targeting of anti-VEGF-NPs after systemic 
injection, we performed in vivo imaging on mice bearing 
colon tumors. On day 14 after CT26 cell inoculation, anti-
VEGF-NPs or NPs were injected via the jugular vein and 
T2*-weighted images obtained using a 7T MRI system. As 
shown in Figure 2C, both the anti-VEGF-NP and NP groups 
gave a bright signal in the tumor before the administration of 
nanoparticles. At 1 hour after injection of anti-VEGF-NPs a 
slight decrease in MRI was noted, as shown by a “blackening 
signal” in the tumor (data not shown). The anti-VEGF-NP 
group showed a marked MRI contrast decrease on days 1 and 
2, followed by a slight decline on day 9. In contrast, the NP 
group showed a slight decrease on day 1, with no change on 
days 2 and 9 when compared to the same animal (controls) 
before NP injection. There was a 1.52 ± 0.15, 1.54 ± 0.14, or 
1.34 ± 0.11-fold change in the MRI signal within the colon 
tumor of the mouse on days 1, 2, or 9 after anti-VEGF-NP 
injection when compared to the control group without nano-
particle injection (Figure 3). In contrast, the signal intensity 
for the NP-injected group did not show any significant dif-
ference from the control value at any time point. The rela-
tive contrast intensity change for the anti-VEGF-NP group 
on days 1 and 2, but not day 9, was significantly increased 
compared to that in the NP group. These results show that 
the anti-VEGF-NPs specifically targeted the colon cancer and 
effectively increased MRI contrast intensity changes.
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Anti-VEgF-NPs, but not NPs,  
are specifically retained in the colon  
cancer mass
To further explore the distribution of anti-VEGF-NPs and NPs 
in colon tumors, Prussian blue staining was used to detect iron, 
representing the location of the nanoparticles.20 As shown in 
Figure 4, Prussian blue staining was seen in cancer sections 
from mice in the anti-VEGF-NP group on days 1, 2, and 9. 
The anti-VEGF-NPs were clearly retained in endothelial cells, 
in the area around blood vessels, and in tumor cells. In contrast, 
Prussian blue staining was mainly observed in endothelial cells 
(and in very few tumor cells) among NP-injected mice on day 1;   
however, no Prussian blue staining was found in the cancer tis-
sues on days 2 and 9. These data show that anti-VEGF-NPs were 
specifically internalized by endothelial cells and tumor cells as 
a result of the overexpression of VEGF in tumor tissues.
To determine the biodistribution of nanoparticles in 
normal tissue in vivo, major organs were harvested, paraffin-
embedded, sectioned, and stained with Prussian blue on days 
1, 2, and 9 after nanoparticle injection. As shown in Figure 5, 
sections from liver and spleen from both the anti-VEGF-NP 
and NP group showed blue iron staining, and the quantity 
of iron deposited was similar on all three days. In contrast, 
Prussian blue-stained cells were rarely detected in sections 
from kidney and lung at any time point.
Figure 4 Anti-VEGF-NPs, but not NPs, are specifically retained in the colon cancer 
mass as shown by Prussian blue staining.
Notes: Tumors were harvested, paraffin-embedded, sectioned, and stained with 
Prussian blue before anti-VEgF-NP or NP injection (Con) or at day 1, 2, or 9 after 
anti-VEgF-NP or NP injection. The arrows indicate the location of nanoparticles. 
Scale bar = 100 µm.
Abbreviations: VEgF-NPs, vascular endothelial growth factor nanoparticles; NPs, 
nanoparticles; Con, control.
Figure 3 MRI contrast intensity changes from the colon tumor region in vivo at the 
indicated time in the anti-VEgF-NP and NP groups.
Notes: Using the MRI signal level of the water phantom as a baseline, there is a 
1.52 ± 0.15, 1.54 ± 0.14, or 1.34 ± 0.11-fold change in the MRI signal within the 
colon tumor of the mouse on day 1, 2, or 9 after anti-VEgF-NP injection compared 
to the control group without nanoparticle injection. The higher level of the relative 
contrast intensity change suggests that more particles accumulated in the tissue. 
The data are expressed as the mean ± SEM for three animals. *Indicates a significant 
difference compared to the control (P , 0.05);  †indicates a significant difference 
between two groups at the indicated time (P , 0.05).
Abbreviations: MRI, magnetic resonance imaging; VEgF-NP, vascular endothelial 
growth factor nanoparticles; NP, nanoparticles; SEM, standard error of the mean; 
P, probability.
Uptake of anti-VEgF-NPs by tumor cells
To confirm the distribution of anti-VEGF-NPs and NPs in 
tumor tissues, TEM was used to visualize the intracellular 
location of nanoparticles. As shown in Figure 6, tumor 
sections from anti-VEGF-NP-injected mice on day 1 after 
injection showed the presence of nanoparticles in the lumen 
of blood vessels, on the plasma membrane, in the cytoplasm 
of endothelial cells (Figure 6A), in the extracellular matrix 
(Figure 6B), and in intracellular granules of tumor cells 
(  Figure 6C). After internalization, the nanoparticles were 
found to be clumped in lysosomes (Figure 6D). In contrast, 
only a few NPs were found in tumor cells and in the cytoplasm 
of endothelial cells (  Figure 6E and F). Figure 6G and H show 
the sections from control non-injected mice.
Discussion
Colon cancer is a highly aggressive tumor with distinct 
histopathological features, including high proliferation 
and necrosis and considerable neovascularization (ie, 
angiogenesis).21 It is generally accepted that the degree of 
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Figure 5 Anti-VEgF-NPs or NPs are present in the spleen and liver, but not the 
lung and kidney, as shown by Prussian blue staining.
Notes: The spleen, liver, lung, and kidney were harvested from mice bearing colon 
tumors, paraffin-embedded, sectioned, and stained with Prussian blue staining at day 
1, 2, or 9 after anti-VEgF-NP or NP injection. Scale bar = 100 µm.
Abbreviations: VEgF-NPs, vascular endothelial growth factor; NPs, nanoparticles.
Figure 6 Representative TEM of tumors in mice treated with anti-VEgF-NPs or NPs.   
On day 1 after nanoparticle injection, the tumors were fixed with paraformaldehyde, 
incubated with osmium tetroxide, and embedded in epoxy resin. Thin sections were 
stained lightly with uranyl acetate and lead citrate to detect uptake of nanoparticles 
into  the  cells.  (A–D)  Anti-VEgF-NPs  were  present  in  the  vascular  lumen  (A), 
endothelial  cells  and  the  matrix  of  surrounding  capillaries  (B),  and  tumor  cells 
(C), and were trapped inside lysosomes (D). (E and F) NPs were present in the 
vascular lumen and the cytoplasm of endothelial cells (E), and seldom found in the 
extracellular matrix and tumor cells (F). (G and H) Tumor sections from mice not 
injected with nanoparticles. The arrows indicate the location of nanoparticles.
Note: Scale bars = 500 nm.
Abbreviations:  TEM,  transmission  electron  micrographs;  VEgF-NPs,  vascular 
endothelial growth factor; NPs, nanoparticles.
angiogenesis correlates with the malignancy of the tumor.22 
VEGF was chosen for our study, since it is an important 
mediator in tumor angiogenesis and the pathogenesis of 
human cancers.13,23 In the present study we demonstrated 
that VEGF was strongly expressed in both human colon 
tumors and a mouse model of colon tumor, whereas little 
or no VEGF expression was seen in normal human colon 
tissue or in other mouse organs by immunohistochemistry. 
Western blotting confirmed the high expression of VEGF 
in CT26 cells and colon tumors. The present study demon-
strated that VEGF is a selective and abundantly expressed 
biomarker in Balb/c mice bearing colon tumors that is similar 
with that in human colon cancer, and that the mice served 
as a good animal model. Use of an animal model could be 
exploited for the selective targeting of tumors for imaging 
and therapeutic applications.
Over the past decade, nanoscience and nanotechnology 
have provided new concepts for the development of cancer 
diagnosis by way of imaging or drug target delivery systems; 
however, challenges for the development of tumor-targeted 
NPs for in vivo applications have also been recognized. 
For instance, the poor penetration of drugs across the 
vascular wall and into the tumor parenchyma against the 
elevated interstitial pressure in tumors remains a major 
problem for tumor therapy.24 In addition, it is important that 
  nanoparticles not only be stable enough to generate strong 
imaging   signals, but that they also have a modified surface with 
reactive functional groups for efficient conjugation of tumor-
targeting ligands and therapeutic agents. Recently, several 
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types of NPs, including magnetic iron oxide, quantum dots, 
gold, and polymer-based NPs, have been developed for can-
cer applications.25–28 Studies have shown that polymer-coated 
NPs, such as the dextran-coated NPs used in the present 
study, have minimal impact on cell viability and function, 
and that they also have low toxicity.18 In addition, dextran-
Fe3O4 NPs have gained attention as nanocarriers given that 
they possess several advantages such as their high stability, 
uniformity of particle size, and high bio-affinity, which 
make them ideal candidates for the passive targeting of solid 
tumor tissue sites as a result of the enhanced permeation and 
retention effect, in which macromolecular agents tend to 
preferentially accumulate in tumor tissues, and the fact they 
can be easily and reproducibly prepared in large quantities.29 
The antibody component attached to the NPs, which allows 
for the differentiation between specific binding to specific 
molecular targets, and which allows for nonspecific bind-
ing in a 2–4 hour timeframe, may also allow monitoring in 
a 12–48 hour window, as the antibody may stay bound for 
a couple of days.20
Our previous study demonstrated that anti-VEGF-NPs 
can be used to explore the relationship between tumor burden 
and the serum VEGF concentration in rats with hepatocel-
lular carcinoma in an immunomagnetic reduction assay.16 In 
the present study, anti-VEGF-NPs were present in the colon 
tumor in mice and showed a high signal-to-noise ratio and 
selective accumulation in the tumor compared to NPs dur-
ing in vivo optical imaging. The optical imaging statistical 
data obtained on days 1, 2, and 9 after nanoparticle injection 
demonstrated a significant change in colon tumor signal in 
the anti-VEGF-NP-treated group compared to the before 
injection control group. However, the data showed that a 
significant change in signal on days 1 and 2 when using 
anti-VEGF-NPs compared to NPs; however, no differences 
were noted on day 9. It was hypothesized that NP was cleared 
and degraded on day 9. This specific issue needs further 
  investigation. Moreover, an added benefit of the anti-VEGF-
NPs developed in this study is the possibility of using MRI 
to powerfully and non-invasively assess tumor formation and 
tumor angiogenesis through high quality anatomic images. 
After imaging, tissue composition, morphology, and function 
can be studied in vivo, allowing serial studies to be performed 
in experimental animals and humans.
The changes in the in vivo MRI signal were correlated 
with Prussian blue staining. Sections from colon tumor-
bearing mice injected with anti-VEGF-NPs, but not NPs, 
showed the presence of nanoparticles in the tumor region 
that colocalized with the tumor cells and endothelial cells. 
Prussian blue-staining confirmed that most of the MRI signal 
in the colon tumor originated from anti-VEGF-NPs, which 
was in contrast to the virtual absence of signal using free NPs. 
Nonspecific biodistribution of anti-VEGF-NPs and NPs was 
seen in the liver and spleen, but not the kidney and lung, and 
the amount of iron deposition did not increase with circula-
tion time. These results are consistent with a previous report 
that NPs can be cleared from the blood and can remain in 
the liver and spleen, which, as part of the reticuloendothelial 
system, have phagocytotic activity.30
Furthermore, at the end of the imaging protocol on day 
1 after injection, tumor sections were analyzed by TEM to 
examine the localization of the injected anti-VEGF-NPs and 
NPs. The VEGF-mediated internalization of the targeted 
nanoparticles into endothelial cells and tumor cells increased 
the number of nanoparticles inside the tumor mass, whereas 
NPs were present in the vascular lumen and endothelial cells, 
but rarely found in tumor cells. These results confirmed 
that the increased tumor optical signal observed through in 
vivo optical imaging resulted from the selective ‘homing’ 
of anti-VEGF-NPs to abnormal VEGF-expressing vessels, 
tumor cells, and stroma in tumor tissues, which was con-
sistent with a previous report that endothelial cells, tumor 
cells, and stroma are important sites of VEGF production 
in tumor tissues,31 making them good molecular targets for 
VEGF-targeted tumor imaging. Similar results of upregula-
tion of VEGF mRNA expression have been reported for the 
vast majority of human tumors examined to date, including 
carcinoma of the lung, breast, gastrointestinal tract, kidney, 
bladder, and ovary.8–11
VEGF  is  strongly  expressed  during  neoplastic 
progression.12 Based on both reports in the literature and 
our findings, the strict localization of anti-VEGF-NPs in 
tumor tissues makes them prime candidates for the detection 
of other cancers and the development of next-generation 
agents for targeted therapy. Our results also showed that 
anti-VEGF-NPs bound to endothelial cells and cancer cells, 
suggesting that when conjugated to an anticancer drug, 
they could be used to inhibit the growth of cancer cells and 
angiogenesis. Moreover, anti-VEGF-NPs -mediated MRI 
employed in the present study could be combined with 
multimodal imaging approaches including PET, SPECT, 
and US, which may lead to improved diagnostic accuracy 
and simultaneous therapy.32
This is the first attempt at detecting in vivo VEGF expres-
sion using dextran-coated F3O4 nanoparticles in conjunction 
with MRI. Anti-VEGF-NPs showed a significantly higher 
uptake by tumor tissues than the control NPs. Anti-VEGF-
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NPs are stable, can retain target specificity for VEGF-
expressing tumor cells, and enable VEGF-targeted MRI of 
colon tumors. Our MRI data, combined with light micro-
scopic and TEM detection of the anti-VEGF probe in tumor 
tissue, provide compelling evidence that this technique can 
be used to detect VEGF levels in vivo in tumor tissues, and 
can also be extended to the applications of tissue engineering, 
which is closely associated with VEGF expression.
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